In response to the Office of April 7, 2004, please amend the application as follows.

IN THE CLAIMS

Claims 1-14 (Cancelled)

Claims 15-25(Withdrawn)

Claim 26 (Cancelled)

Claim 27 (Cancelled)

Claim 28 (Withdrawn)

29. (Currently Amended) An inclusion complex of paroxetine, as a free base or as a salt, with a cyclodextrin [or with a cyclodextrin derivative].

30. (Previously Presented) The inclusion complex as claimed in claim 29, wherein it is in the form of a flowing powder, it has a greater stability in comparison with the non-complexed paroxetine, organic solvents are absent, it has a higher solubility in water with respect to the non-complexed paroxetine and a DSC profile different from that of the corresponding non-complexed paroxetine or paroxetine salt.

31. (Previously Presented) The inclusion complex as claimed in claim 30, wherein ethanol is absent.

32. (Previously Presented) The inclusion complex as claimed in claim 29, having a water content of between 1 and 20% by weight.

33. (Previously Presented) The inclusion complex as claimed in claim 32, having a water content is between 2 and 15% by weight.

34. (Previously Presented) The inclusion complex as claimed in claim 29, wherein the cyclodextrin is selected from the group consisting of α, β and γ-cyclodextrin.

35. (Previously Presented) The inclusion complex as claimed in claim 34, wherein the cyclodextrin is a β-cyclodextrin.

36. (Cancelled)

37. (Cancelled)

38. (Previously Presented) The inclusion complex as claimed in claim 29, wherein the salt of paroxetine is a salt with an organic or inorganic acid.

39. (Previously Presented) The inclusion complex as claimed in claim 38, wherein said organic or inorganic acid is selected from the group consisting of acetic acid, maleic acid, hydrochloric acid and methanesulfonic acid.

40. (Previously Presented) The inclusion complex as claimed in claim 39, wherein said acid is hydrochloric acid.

41. (Currently Amended) The inclusion complex as claimed in claim 29, wherein the molar ratio between paroxetine and said cyclodextrin [or cyclodextrin derivative] ranges from 1:0.25 to 1:20.

42. (Currently Amended) The inclusion complex as claimed in claim 41, wherein the molar ratio between paroxetine and said cyclodextrin [or cyclodextrin derivative] ranges from 1:0.5 to 1:2.

43. (Previously Presented) A pharmaceutical composition containing as an active substance a pharmaceutically effective dose of an inclusion complex as defined in claim 29, in mixture with pharmaceutically acceptable diluents or excipients.

44. (Previously Presented) The pharmaceutical composition as claimed in claim 43 in solid or liquid form, for oral and for parenteral administration.

45. (New) An inclusion complex of paroxetine, as a free base or as a salt, with a cyclodextrin derivative, wherein said inclusion complex is in the form of a flowing powder, has a greater stability in comparison with the non-complexed paroxetine, is free from organic solvents, has a higher solubility in water with respect to the non-complexed paroxetine and a DSC profile different from that of the corresponding non-complexed paroxetine or paroxetine salt.

46. (New) The inclusion complex as claimed in claim 45, wherein ethanol is absent.

47. (New) The inclusion complex as claimed in claim 45, wherein said salt of paroxetine is a salt with an organic or inorganic acid.

48. (New) The inclusion complex as claimed in claim 47, wherein said organic or inorganic acid is selected from the group consisting of acetic acid, maleic acid, hydrochloric acid and methanesulfonic acid.

49. (New) The inclusion complex as claimed in claim 48, wherein said acid is hydrochloric acid.

50. (New) The inclusion complex as claimed in claim 45, wherein the molar ratio between paroxetine and said cyclodextrin derivative ranges from 1:0.25 to 1:20.

51. (New) The inclusion complex as claimed in claim 50, wherein the molar ratio between paroxetine and said cyclodextrin derivative ranges from 1:0.5 to 1:2.

52. (New) The inclusion complex as claimed in claim 45, wherein said cyclodextrin derivative is selected from the group consisting of heptakis (2,6-di-O-methyl)-β-cyclodextrin, heptakis (2,3,6-tri-O-methyl)-β-cyclodextrin, monosuccinyl-heptakis(2,6-di-O-methyl)-β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, sulphated cyclodextrin and cyclodextrin containing aminoalkyl groups.

53. (New) The inclusion complex as claimed in claim 52, wherein said cyclodextrin derivative is the 2-hydroxypropyl-β-cyclodextrin.

54. (New) A pharmaceutical composition containing as an active substance a pharmaceutically effective dose of an inclusion complex as defined in claim 45, in mixture with pharmaceutically acceptable diluents or excipients.

55. (New) The pharmaceutical composition as claimed in claim 54, in solid or liquid form, for oral and for parenteral administration.